Century Therapeutics IPSC Presents 11-Month Efficacy Data for CNTY-813 Diabetes Therapy

Key highlights

• CNTY-813 restored normoglycemia in streptozotocin-induced diabetic mice throughout an 11-month study
• Clinical manufacturing consistency confirmed across five clinical-scale production batches
• Therapeutic islets remained functional after 96 hours of cold storage, supporting supply chain viability
• Successful engraftment demonstrated via liver portal vein delivery in rat models
• Initial clinical data from proposed Phase 1/2 trials anticipated in the second half of 2027

Updated Nonclinical Outcomes

The latest data presented at the European Association for the Study of Diabetes in Milan highlights the durability of CNTY-813, which is engineered with the company's Allo-Evasion 5.0 technology. In streptozotocin-induced diabetic mice, the therapy rapidly restored normoglycemia and maintained stable glycemic control until the graft was surgically removed after more than eleven months. Potency testing revealed that the iPSC-derived islets exhibited glucose-stimulated insulin secretion levels comparable to primary islets, suggesting high pharmacological activity. The study further validated that all treated mice achieved normoglycemia, reinforcing the therapeutic potential of the cell-based approach for type 1 diabetes.

Manufacturing and Logistics Milestones

• Production consistency validated through five separate clinical-scale runs from a GMP Master Cell Bank
• The 29-day manufacturing process met or exceeded purity criteria at every production stage
• Cold storage stability verified for up to 96 hours without loss of therapeutic function in vivo
• Engrafted islets in rats stained positive for insulin and chromogranin A one month post-transplant
• Liver portal vein delivery confirmed as a viable clinical route of administration for future human trials

Executive Perspective

“Following our pre-IND meeting, in which we reached general alignment with FDA on our nonclinical package, Phase 1 manufacturing process and proposed Phase 1/2 trial design, we remain on track to submit the CNTY-813 IND in the fourth quarter of this year.”

Business Overview

Century Therapeutics is a Philadelphia-based biotechnology firm specializing in the development of induced pluripotent stem cell-derived therapies. The company's proprietary platform integrates advanced gene editing and immune evasion technologies to create off-the-shelf cell products for autoimmune diseases and oncology. By utilizing iPSCs as a starting material, the company aims to overcome the scalability and consistency challenges inherent in traditional cell therapies. Its current pipeline includes programs targeting B-cell mediated diseases and Type 1 Diabetes, leveraging a standardized manufacturing infrastructure to support multi-product clinical development.

Financial and Market Context

Century Therapeutics currently carries a market capitalization of approximately $277 million, with annual revenue reported at $109.16 million. Technical indicators show the stock's Relative Strength Index at 27.8, which typically signals an oversold condition in the market. The stock has faced significant volatility recently, recording a 24.63% decline over the last month and a 37.55% decrease over the previous quarter. Despite the share price performance, the company maintains its clinical timeline for its diabetes program, with the upcoming fourth-quarter IND filing serving as a critical regulatory milestone.

Down 14.3% since our story on 2 Oct: $1.61 when we broke it → $1.38 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$2.00
15 Sep	$1.98
16 Sep	$1.86
17 Sep	$1.88
18 Sep	$1.86
21 Sep	$1.85
22 Sep	$1.89
23 Sep	$1.76
24 Sep	$1.69
25 Sep	$1.67
28 Sep	$1.67
29 Sep	$1.65
30 Sep	$1.71
1 Oct	$1.61
2 Oct	$1.53
5 Oct	$1.48
6 Oct	$1.32
7 Oct	$1.28
8 Oct	$1.46
9 Oct	$1.47
12 Oct	$1.44
13 Oct	$1.38

Management commentary

“The data presented at EASD build on the nonclinical package we presented at ADA in June and highlight our continued execution on bringing CNTY-813 into the clinic.”

Century Therapeutics, Inc. · financial snapshot

Share price	$1.61
Market cap	$277M
Revenue (annual)	$109M
1-month price change	-24.63%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.